Kurzfassung

A phase III, open-label, multicenter, randomized study of sequential Zevalin (Ibritumomab Tiuxetan) versus observation in patients at least 60 years of age with newly diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy